Stifel analysts upgraded Edwards Lifesciences (NYSE:EW) stock from Hold to Buy, citing potential growth acceleration in the Transcatheter Aortic Valve Replacement (TAVR) market. The firm also ...
Stifel analyst Rick Wise upgraded Edwards Lifesciences (EW) to Buy from Hold with a price target of $90, up from $75. The firm said that TAVR, ...
Wolfe Research downgraded Edwards Lifesciences (EW) to Underperform from Peer Perform with a $60 price target The firm says its core ...
GlobalData analysts anticipate FDA approval for the JenaValve Trilogy TAVR device designed to treat aortic regurgitation (AR) ...
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”) ...
Edwards Lifesciences Corporation (NYSE ... As we noted earlier this year, the Company's flagship transcatheter aortic valve replacement (TAVR) franchise slowed as compared to the Company's recent ...
He has also acted as a Consultant for Sorin and received research support from Edwards Lifesciences. Jean G. Dumesnil received Speakers' Bureau honoraria from Medtronic and St Jude Medical.
These techniques include coronary sinus annuloplasty, direct annuloplasty, leaflet repair ... (Edwards Lifesciences, Inc., CA, USA) valve is a balloon-expandable, bovine pericardial interventional ...
News Medical on MSN2d
Mechanical valves offer superior long-term survival for aortic valve replacement patients agedAnnual Meeting reveals that mechanical aortic valve replacements (AVRs) provide significant long-term survival benefits for ...
SGMC Health recently achieved the successful completion of its first transcarotid access Transcatheter Aortic Valve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback